Tamsulosina Quasset may be available in the countries listed below.
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Tamsulosina Quasset in the following countries:
International Drug Name Search
Trosid Uñas may be available in the countries listed below.
Tioconazole is reported as an ingredient of Trosid Uñas in the following countries:
International Drug Name Search
Nitrocap may be available in the countries listed below.
Nitroglycerin is reported as an ingredient of Nitrocap in the following countries:
International Drug Name Search
Tamsulosine HCl Katwijk may be available in the countries listed below.
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Tamsulosine HCl Katwijk in the following countries:
International Drug Name Search
Trepidan may be available in the countries listed below.
Prazepam is reported as an ingredient of Trepidan in the following countries:
International Drug Name Search
Abalgin may be available in the countries listed below.
Dextropropoxyphene hydrochloride (a derivative of Dextropropoxyphene) is reported as an ingredient of Abalgin in the following countries:
International Drug Name Search
Generic Name: calcitonin (Parenteral route)
kal-si-TOE-nin
Calcitonin is used to treat Paget's disease of bone. It also may be used to prevent continuing bone loss in women with postmenopausal osteoporosis and to treat hypercalcemia (too much calcium in the blood). This medicine may be used to treat other conditions as determined by your doctor.
This medicine is available only with your doctor's prescription.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although this use is not included in product labeling, calcitonin is used in certain patients with the following medical condition:
Tell your doctor if you have ever had any unusual or allergic reaction to medicines in this group or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Studies on this medicine have been done only in adult patients, and there is no specific information comparing the use of calcitonin in children with use in other age groups. Therefore, be sure to discuss with your doctor the use of this medicine in children.
Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults. Although there is no specific information comparing the use of calcitonin in the elderly with use in other age groups, this medicine is not expected to cause different side effects or problems in older people than it does in younger adults. Calcitonin is often used in elderly patients.
Calcitonin has not been studied in pregnant women. However, in animal studies, calcitonin has been shown to lower the birth weight of the baby when the mother was given a dose of calcitonin many times the human dose.
Calcitonin has not been reported to cause problems in nursing babies. However, studies in animals have shown that calcitonin may decrease the flow of breast milk.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
This section provides information on the proper use of a number of products that contain calcitonin. It may not be specific to Miacalcin. Please read with care.
Make certain your health care professional knows if your diet includes large amounts of calcium-containing foods and/or vitamin D-containing foods, such as milk or other dairy products. Calcium and vitamin D may cause the calcitonin to be less effective in treating a high blood calcium. Also let your health care professional know if you are on any special diet, such as low-sodium or low-sugar diet.
This medicine is for injection only. If you will be giving yourself the injections, make sure you understand exactly how to give them, including how to fill the syringe before injection. If you have any questions about this, check with your doctor.
Use the calcitonin only when the contents of the syringe are clear and colorless. Do not use it if it looks grainy or discolored.
The dose medicines in this class will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of these medicines. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
Call your doctor or pharmacist for instructions.
If you miss a dose of this medicine and your dosing schedule is:
If you have any questions about this, check with your doctor.
Keep out of the reach of children.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Do not keep outdated medicine or medicine no longer needed.
Store calcitonin-human at a temperature below 77 °F. Do not refrigerate. Use prepared solution within 6 hours.
Store calcitonin-salmon in the refrigerator. However, keep it from freezing.
Your doctor should check your progress at regular visits to make sure that this medicine does not cause unwanted effects.
If you are using this medicine for hypercalcemia (too much calcium in the blood), your doctor may want you to follow a low-calcium diet. If you have any questions about this, check with your doctor.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: Miacalcin Parenteral side effects (in more detail)
The information contained in the Thomson Healthcare (Micromedex) products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Healthcare does not assume any responsibility or risk for your use of the Thomson Healthcare products.
Truxaletten may be available in the countries listed below.
Chlorprothixene hydrochloride (a derivative of Chlorprothixene) is reported as an ingredient of Truxaletten in the following countries:
International Drug Name Search
Tropico may be available in the countries listed below.
Tropicamide is reported as an ingredient of Tropico in the following countries:
International Drug Name Search
Diclofenac-Eurogenerics may be available in the countries listed below.
Diclofenac is reported as an ingredient of Diclofenac-Eurogenerics in the following countries:
International Drug Name Search
Lirpan may be available in the countries listed below.
Donepezil hydrochloride (a derivative of Donepezil) is reported as an ingredient of Lirpan in the following countries:
International Drug Name Search
Fenistil Hydrocort may be available in the countries listed below.
Hydrocortisone is reported as an ingredient of Fenistil Hydrocort in the following countries:
International Drug Name Search
Tansulosina Sandoz may be available in the countries listed below.
Tamsulosin is reported as an ingredient of Tansulosina Sandoz in the following countries:
International Drug Name Search
In the US, Tapentadol (tapentadol systemic) is a member of the drug class narcotic analgesics and is used to treat Pain.
US matches:
Rec.INN
N02AX06
0175591-23-8
C14-H23-N-O
221
Analgesic
Opioid analgesic
3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol (WHO)
International Drug Name Search
Glossary
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
| WHO | World Health Organization |
Tamsulosin Interpharm retard may be available in the countries listed below.
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Tamsulosin Interpharm retard in the following countries:
International Drug Name Search
Tocorell Vit. E may be available in the countries listed below.
Tocopherol, α- is reported as an ingredient of Tocorell Vit. E in the following countries:
International Drug Name Search
Diosmine EG may be available in the countries listed below.
Diosmin is reported as an ingredient of Diosmine EG in the following countries:
International Drug Name Search
Amiloride hydrochloride dihydrate (a derivative of Amiloride) is reported as an ingredient of Hydro-ride in the following countries:
Hydrochlorothiazide is reported as an ingredient of Hydro-ride in the following countries:
International Drug Name Search
Tamsulosin-EG may be available in the countries listed below.
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Tamsulosin-EG in the following countries:
International Drug Name Search
Marcain Dental may be available in the countries listed below.
Bupivacaine hydrochloride (a derivative of Bupivacaine) is reported as an ingredient of Marcain Dental in the following countries:
Epinephrine is reported as an ingredient of Marcain Dental in the following countries:
International Drug Name Search
Relieving symptoms of sinus congestion, runny nose, sneezing, itchy nose or throat, itchy or watery eyes, cough due to colds, upper respiratory tract infections, and allergies. It may also be used for other conditions as determined by your doctor.
Viravan-PDM Suspension is a decongestant, antihistamine, and cough suppressant combination. The decongestant works by constricting blood vessels and reducing swelling in the nasal passages. The antihistamine works by blocking the action of histamine, which helps reduce symptoms such as watery eyes and sneezing. The cough suppressant works in the brain to help decrease the cough reflex to reduce a dry cough.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Viravan-PDM Suspension. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Viravan-PDM Suspension. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Viravan-PDM Suspension may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Viravan-PDM Suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Viravan-PDM Suspension.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; drowsiness; dry mouth, nose, or throat; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; difficulty urinating or inability to urinate; fast or irregular heartbeat; fever, chills, or persistent sore throat; hallucinations; loss of coordination; mental or mood changes (eg, depression); seizures; severe dizziness, drowsiness, lightheadedness, or headache; severe dryness of mouth, nose, and throat; severe or persistent trouble sleeping; shortness of breath; tremor; unusual bruising or bleeding; unusual tiredness or weakness; vision problems (eg, double vision, severe or persistent blurred vision).
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Viravan-PDM side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; flushing; hallucinations; mental or mood changes; muscle spasms; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; trouble breathing; unusually fast, slow, or irregular heartbeat; vomiting.
Store Viravan-PDM Suspension at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Viravan-PDM Suspension out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Viravan-PDM Suspension. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Cipflox may be available in the countries listed below.
Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of Cipflox in the following countries:
International Drug Name Search
Tamsulosina Mabo may be available in the countries listed below.
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Tamsulosina Mabo in the following countries:
International Drug Name Search
Vislube may be available in the countries listed below.
Hyaluronic Acid sodium salt (a derivative of Hyaluronic Acid) is reported as an ingredient of Vislube in the following countries:
International Drug Name Search
Tramadolor retard may be available in the countries listed below.
Tramadol hydrochloride (a derivative of Tramadol) is reported as an ingredient of Tramadolor retard in the following countries:
International Drug Name Search
Tencas may be available in the countries listed below.
Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Tencas in the following countries:
International Drug Name Search
Tamsulosin Winthrop may be available in the countries listed below.
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Tamsulosin Winthrop in the following countries:
International Drug Name Search
In the US, Truphylline (aminophylline systemic) is a member of the drug class methylxanthines and is used to treat Apnea of Prematurity and Asthma - acute.
US matches:
Aminophylline is reported as an ingredient of Truphylline in the following countries:
International Drug Name Search
Tilodene may be available in the countries listed below.
Ticlopidine hydrochloride (a derivative of Ticlopidine) is reported as an ingredient of Tilodene in the following countries:
International Drug Name Search
Denufam may be available in the countries listed below.
Famotidine is reported as an ingredient of Denufam in the following countries:
International Drug Name Search
Acido Alendronico Edigen may be available in the countries listed below.
Alendronic Acid sodium trihydrate (a derivative of Alendronic Acid) is reported as an ingredient of Acido Alendronico Edigen in the following countries:
International Drug Name Search
Trusil may be available in the countries listed below.
Tropicamide is reported as an ingredient of Trusil in the following countries:
International Drug Name Search
Tamsulosina Davur may be available in the countries listed below.
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Tamsulosina Davur in the following countries:
International Drug Name Search
Topiramat Spirig may be available in the countries listed below.
Topiramate is reported as an ingredient of Topiramat Spirig in the following countries:
International Drug Name Search
Tamsulosina Eg may be available in the countries listed below.
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Tamsulosina Eg in the following countries:
International Drug Name Search
Instillagel may be available in the countries listed below.
Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Instillagel in the following countries:
Lidocaine hydrochloride (a derivative of Lidocaine) is reported as an ingredient of Instillagel in the following countries:
Lidocaine hydrochloride monohydrate (a derivative of Lidocaine) is reported as an ingredient of Instillagel in the following countries:
International Drug Name Search
Melperon Sandoz may be available in the countries listed below.
Melperone hydrochloride (a derivative of Melperone) is reported as an ingredient of Melperon Sandoz in the following countries:
International Drug Name Search
Aredia is a brand name of pamidronate, approved by the FDA in the following formulation(s):
Yes. The following products are equivalent to Aredia:
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aredia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Aredia.
Tamsulosina Edigen may be available in the countries listed below.
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Tamsulosina Edigen in the following countries:
International Drug Name Search
MEG-loo-meen an-ti-MOE-nee-ate
Meglumine antimoniate belongs to the group of medicines called antiprotozoals. Meglumine antimoniate is used to treat an infection called leishmaniasis (Bay sore or chiclero ulcer, espundia, kala-azar or black sickness, Oriental sore, ulcera de Bejuco, uta), which is caused by protozoa (tiny, one-celled organisms).
Meglumine antimoniate should be administered by or under the supervision of your doctor.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For meglumine antimoniate, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to meglumine antimoniate or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Although there is no specific information comparing use of meglumine antimoniate in children with use in other age groups, meglumine antimoniate is not expected to cause different side effects or problems in children than it does in adults.
Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing use of meglumine antimoniate in the elderly with use in other age groups.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
The presence of other medical problems may affect the use of meglumine antimoniate. Make sure you tell your doctor if you have any other medical problems, especially:
To help clear up your infection completely, meglumine antimoniate is based on its amount of pentavalent antimony and must be given for the full time of treatment and on a regular schedule.
The dose of meglumine antimoniate will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of meglumine antimoniate. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
It is important that your doctor check your progress at regular visits. This is to help make sure that the infection is cleared up completely.
If your symptoms become worse, check with your doctor .
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
Tensiomax may be available in the countries listed below.
Cyclobenzaprine hydrochloride (a derivative of Cyclobenzaprine) is reported as an ingredient of Tensiomax in the following countries:
International Drug Name Search
The wording of leaflets is regularly updated. This electronic text is the most up-to-date version and may differ from the leaflet in your pack. If you have any questions about the information provided, please ask your doctor or pharmacist.
VELOSEF FOR INJECTION
Cefradine
Your doctor has prescribed Velosef for Injection for you. This leaflet gives a summary of information about your medicine. If you want to know more, or are not sure about anything, ask your doctor or pharmacist.
The active ingredient in Velosef is cefradine. Velosef is available in two strengths and each vial contains either 500mg or 1g cefradine. Cefradine is an antibiotic and a member of the family of medicines called cephalosporins. The other ingredient is L-arginine. The powder in the vial is dissolved in water for injections or another infusion fluid before administration.
Velosef is used to treat bacterial infections in the chest, urinary tract or skin. The injection is given when patients are unable to take an oral antibiotic medicine or when the infection needs to be treated quickly. Velosef is also used to treat infections after surgery.
Tell your doctor if you are allergic to any of the ingredients in Velosef or similar medicines such as other cephalosporins and penicillins.
If you are pregnant, planning to become pregnant or breast feeding, speak to your doctor.
Tell your doctor about any previous problems with your liver or kidneys, as the dose of Velosef may need to be adjusted. Your doctor may want to monitor your liver or kidney function whilst you are taking Velosef.
If you use chemical tests to check for sugar in the urine, Velosef may cause a false positive reaction. This does not occur with dipstick type tests. Ask your doctor which type of test kit you should use.
If you are taking any other medicines it is important to discuss this with your doctor or pharmacist. These include furosemide (‘water tablets’) or probenecid and medicines bought at a pharmacy or elsewhere e.g. supermarket.
There is no interaction between Velosef and moderate amounts of alcohol. However, you should check with your doctor whether drinking is advisable for you.
Velosef will be given by injection into a large muscle, or slow injection into a vein, or as an intravenous drip. Your doctor will decide what dose is required and how long the treatment should continue, based on your symptoms and the results of blood tests. The usual dose for treatment of infections is 2-4g daily, given in four equally divided doses. The dose given for prevention of infections after surgery is 1-2g. The usual dose for children is 50-100mg/kg bodyweight/day.
In a few patients, especially those with a history of allergy, asthma, hay fever or nettle rash, Velosef may cause diarrhoea or a rash. Skin and hypersensitivity reactions may include unexpected itchy red swelling on skin, fever, joint pain or fluid retention. More rarely, there have been reports of inflammation of the tongue, heartburn, headache, dizziness, shortness of breath, pins and needles, nausea, vomiting, abdominal pain, fungal infections, vaginal inflammation. Occasionally, patients complain of pain, bruising and inflammation at the injection site. Very rarely, blood/liver disorders occur and any diarrhoea with blood and mucus should be reported to your doctor, nurse or pharmacist. There have also been very rare reports of more serious allergic reactions including anaphylaxis and Stevens Johnson syndrome. If you notice any other unusual or unexpected symptoms tell your doctor or pharmacist.
This medicine will be stored in the pharmacy until it is given to you by your doctor or nurse. It should not be stored above 25°C. It should not be used after the expiry date shown on the outer packaging.
DATE OF PREPARATION October 2005
PLEASE DETACH BEFORE HANDING ABOVE SECTION TO THE PATIENT
VELOSEF
FOR INJECTION
Paracetamol Extra Fort may be available in the countries listed below.
Paracetamol is reported as an ingredient of Paracetamol Extra Fort in the following countries:
International Drug Name Search
Tenpril may be available in the countries listed below.
Captopril is reported as an ingredient of Tenpril in the following countries:
International Drug Name Search
Azithral may be available in the countries listed below.
Azithromycin dihydrate (a derivative of Azithromycin) is reported as an ingredient of Azithral in the following countries:
International Drug Name Search
Cletus may be available in the countries listed below.
Omeprazole is reported as an ingredient of Cletus in the following countries:
International Drug Name Search
Tenkdol may be available in the countries listed below.
Ketorolac tromethamine (a derivative of Ketorolac) is reported as an ingredient of Tenkdol in the following countries:
International Drug Name Search
Tropikamid Chauvin may be available in the countries listed below.
Tropicamide is reported as an ingredient of Tropikamid Chauvin in the following countries:
International Drug Name Search
Sertralina Aserta may be available in the countries listed below.
Sertraline hydrochloride (a derivative of Sertraline) is reported as an ingredient of Sertralina Aserta in the following countries:
International Drug Name Search
Troxérutine Arrow may be available in the countries listed below.
Troxerutin is reported as an ingredient of Troxérutine Arrow in the following countries:
International Drug Name Search
Topcort may be available in the countries listed below.
Desoximetasone is reported as an ingredient of Topcort in the following countries:
Mometasone 17-(2-furoate) (a derivative of Mometasone) is reported as an ingredient of Topcort in the following countries:
International Drug Name Search
Kuppam may be available in the countries listed below.
Pantoprazole sodium (a derivative of Pantoprazole) is reported as an ingredient of Kuppam in the following countries:
International Drug Name Search
Tensiomin may be available in the countries listed below.
Captopril is reported as an ingredient of Tensiomin in the following countries:
International Drug Name Search
Xalaprost may be available in the countries listed below.
Latanoprost is reported as an ingredient of Xalaprost in the following countries:
International Drug Name Search
Tamsulosin-CT may be available in the countries listed below.
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Tamsulosin-CT in the following countries:
International Drug Name Search
Terbinafina Combix may be available in the countries listed below.
Terbinafine hydrochloride (a derivative of Terbinafine) is reported as an ingredient of Terbinafina Combix in the following countries:
International Drug Name Search
Tru may be available in the countries listed below.
Pyrvinium Pamoate is reported as an ingredient of Tru in the following countries:
International Drug Name Search
Diflu may be available in the countries listed below.
Fluconazole is reported as an ingredient of Diflu in the following countries:
International Drug Name Search
Troxérutine Merck may be available in the countries listed below.
Troxerutin is reported as an ingredient of Troxérutine Merck in the following countries:
International Drug Name Search
Statum may be available in the countries listed below.
Clotrimazole is reported as an ingredient of Statum in the following countries:
International Drug Name Search
BAN
B06AA07,D03BA01
0009002-07-7
Wound healing agent
Proteolytic enzyme
Proteolytic enzyme crystallized from an extract of the pancreas gland of the ox, Bos taurus
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
Tenchlor may be available in the countries listed below.
Atenolol is reported as an ingredient of Tenchlor in the following countries:
Chlortalidone is reported as an ingredient of Tenchlor in the following countries:
International Drug Name Search
Trimébutine Winthrop may be available in the countries listed below.
Trimebutine maleate (a derivative of Trimebutine) is reported as an ingredient of Trimébutine Winthrop in the following countries:
International Drug Name Search
Imiject may be available in the countries listed below.
Sumatriptan succinate (a derivative of Sumatriptan) is reported as an ingredient of Imiject in the following countries:
International Drug Name Search
Torped may be available in the countries listed below.
Cefradine is reported as an ingredient of Torped in the following countries:
International Drug Name Search
Trimetaratio may be available in the countries listed below.
Trimetazidine dihydrochloride (a derivative of Trimetazidine) is reported as an ingredient of Trimetaratio in the following countries:
International Drug Name Search
Tetravet 200LA may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Oxytetracycline dihydrate (a derivative of Oxytetracycline) is reported as an ingredient of Tetravet 200LA in the following countries:
International Drug Name Search
Tamsulosine Winthrop may be available in the countries listed below.
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Tamsulosine Winthrop in the following countries:
International Drug Name Search
Teniverm may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Levamisole hydrochloride (a derivative of Levamisole) is reported as an ingredient of Teniverm in the following countries:
Niclosamide is reported as an ingredient of Teniverm in the following countries:
Tetramisole hydrochloride (a derivative of Tetramisole) is reported as an ingredient of Teniverm in the following countries:
International Drug Name Search
Tamsulosine Ratiopharm may be available in the countries listed below.
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Tamsulosine Ratiopharm in the following countries:
International Drug Name Search
Generic Name: Naftifine Hydrochloride
Class: Allylamines
ATC Class: D01AE22
VA Class: DE102
Chemical Name: (E)-N-Methyl-N-(3-phenyl-2-propenyl)-1-naphthalenemethanamine hydrochloride
Molecular Formula: C21H21N•HCl
CAS Number: 65473-14-5
Antifungal; synthetic allylamine structurally and pharmacologically related to terbinafine.1 3 4 5 9 11 13 14 16 21 22 23 25 29 31 35 36 37 38 41 42 43 48 63 64 65 66 67 68 69
Treatment of tinea corporis (body ringworm)1 22 39 46 48 49 50 51 54 55 63 and tinea cruris (jock itch)1 22 23 39 45 48 49 50 51 54 55 63 caused by Epidermophyton floccosum,1 39 45 47 49 50 51 53 63 Microsporum canis†,49 50 55 Trichophyton mentagrophytes,1 39 47 49 50 51 53 55 63 T. rubrum,1 T. tonsurans,a T. verrucosum†,50 51 53 or T. violaceum†.50
Treatment of tinea pedis (athlete's foot)1 15 28 47 48 49 51 54 55 63 or tinea manuum†51 54 55 caused by Epidermophyton floccosum,1 39 45 47 49 50 51 53 63 Microsporum canis†,49 50 55 Trichophyton mentagrophytes,1 39 47 49 50 51 53 55 63 T. rubrum,1 T. tonsurans,a T. verrucosum†,50 51 53 or T. violaceum†.50
Topical antifungals usually effective for treatment of uncomplicated tinea corporis and tinea cruris.69 70 71 72 73 An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, the infection is chronic or does not respond to topical therapy, or the patient is immunocompromised because of coexisting disease or concomitant therapy.69 70 71 72 73
Topical antifungals usually effective for treatment of uncomplicated tinea pedis.69 70 71 72 73 An oral antifungal may be necessary for the treatment of hyperkeratotic areas on the palms and soles,70 73 for chronic moccasin-type (dry-type) tinea pedis,69 70 72 and for tinea unguium (fingernail or toenail dermatophyte infections, onychomycosis).69 70 71 72
Gel has been used in the treatment of tinea unguium (onychomycosis)†.57
Treatment of cutaneous candidiasis† caused by Candida albicans.47 50 51 53 54 55 56 62 Less active than imidazole derivatives.36 37 56
Apply topically to the skin as a cream or gel.1 63
Do not apply to the eye, nose, mouth, or other mucous membranes.1 63
Do not use with occlusive dressings or wrappings, unless otherwise directed by clinician.1 63
Apply a sufficient amount of topical cream or gel; rub gently into the affected area and surrounding skin.1 22 33 39 46 47 49 50 51 53 54 60 63
Wash hands after applying.1 63
Available as naftifine hydrochloride; dosage expressed in terms of naftifine.a
Cream: Apply once daily for 2–4 weeks.1 15 22 25 33 39 45 46 49 53 54 60
Gel: Apply twice daily (morning and evening) for 2–4 weeks.22 25 39 45 46 49 a
Clinical improvement usually occurs within the first week of treatment.22 25 39 45 If clinical improvement does not occur after 4 weeks of treatment, reevaluate diagnosis.1 63 Severe infections may require prolonged treatment.50 60 61
Cream: Apply once daily for 4–6 weeks.1 15 22 15 25 33 39 45 46 47 49 53 54 60
Gel: Apply twice daily (morning and evening) for 4–6 weeks.15 22 25 39 45 46 47 49 a
Clinical improvement usually occurs within the first week of treatment.22 25 39 45 If clinical improvement does not occur after 4 weeks of treatment, reevaluate diagnosis.1 63 Severe infections may require prolonged treatment.50 60 61
No special population dosage recommendations at this time.a
Known hypersensitivity to naftifine or any ingredient in the formulation. 1 63
For external use only.1 63 Use only for topical application to the skin; not for ophthalmic use.1 63
Avoid contact with eyes, nose, mouth, and other mucous membranes.1 63
Contact dermatitis has been reported occasionally.20 39 49 54 56
If irritation or sensitivity occurs, discontinue drug and initiate appropriate therapy.1 63
Prior to use, confirm diagnosis by direct microscopic examination of scrapings from infected tissue mounted in potassium hydroxide (KOH) or by culture.1 63
Category B.a
Not known whether distributed into milk following topical application.1 63 Use with caution.1 63
Safety and efficacy not established.a
Burning, stinging.1 22 32 39 46 47 50 51 55 63
No formal drug interaction studies to date.
Following topical application, approximately 3–6% absorbed.1 43 63
Not known whether naftifine crosses the placenta.60
Distributed into milk in rats; not known whether distributed into human milk.1 43 60 63
Metabolized by oxidation and by N-dealkylation.18
Systemically absorbed drug excreted in urine (40–60%) as unchanged drug and metabolites and in feces.1 18 43 63
2–3 days.1 60 63
<30°C;1 cream is stable for 24 months after the date of manufacture.60
Room temperature.63
Allylamine antifungal.1 3 4 5 9 11 13 14 16 21 22 23 25 29 31 35 36 37 38 41 42 43 48 63
Usually fungicidal against susceptible dermatocytes.1 9 14 41 42 Usually fungistatic against Candida; may be fungicidal at high concentrations.1 3 9 14 41 42
Exact mechanism unknown; 1 3 11 16 41 43 appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene monooxygenase (squalene 2,3-epoxidase).1 11 13 14 16 21 41 43 The resulting accumulation of squalene (the usual substrate of the enzyme) in the cells and decreased amounts of sterols, especially ergosterol,1 3 10 11 16 41 may contribute to the antifungal effects.41
Spectrum of antifungal activity includes many fungi, including dermatophytes and yeasts.1 2 3 4 5 8 9 12 22 23 31 37 42 Also may have in vitro activity against some gram-positive and -negative bacteria,58 60 61 and Leishmania.27
Candida: Active in vitro against Candida albicans,1 3 4 12 36 C. krusei,4 C. parapsilosis,4 12 31 41 and C. tropicalis;12 however, less active than imidazole derivatives against Candida.36 37 56
Dermatophytes and other fungi: Active in vitro against Aspergillus flavus,12 A. fumigatus,12 Blastomyces dermatitidis,12 Cryptococcus neoformans,12 Epidermophyton floccosum,1 4 8 12 38 42 Histoplasma capsulatum,12 Microsporum audouinii,1 M. canis,1 8 38 42 M. gypseum,1 8 Petriellidium boydii,12 Sporothrix schenckii,4 12 Trichophyton mentagrophytes,1 2 8 38 41 42 T. rubrum,1 8 38 42 T. tonsurans,1 38 T. verrucosum,42 and T. violaceum.8 38
Also has anti-inflammatory activity when applied topically.51 52
No reports to date of resistance in organisms originally susceptible to naftifine.60 61
Importance of completing full course of treatment, even if symptoms improve.1
Importance of contacting clinician if improvement does not occur within 4 weeks.1 63
Importance of notifying clinician if condition worsens or treated area shows signs of increased irritation.a
Importance of applying to affected areas as directed and avoiding contact with eyes, nose, mouth, or other mucous membranes.1 63
Advise patients to wash their hands after touching the affected areas.a
Importance of not using occlusive dressings, unless otherwise directed by clinician.1 63
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.a
Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.a
Importance of informing patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Topical | Cream | 1% | Naftin (with benzyl alcohol) | Merz |
Gel | 1% | Naftin (with alcohol 52% v/v) | Merz |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Naftin 1% Cream (MERZ PHARMACEUTICAL): 30/$109.99 or 90/$285.96
Naftin 1% Cream (MERZ PHARMACEUTICAL): 60/$190 or 180/$559.94
Naftin 1% Cream (MERZ PHARMACEUTICAL): 90/$239.98 or 270/$676
Naftin 1% Gel (MERZ PHARMACEUTICAL): 40/$155.99 or 120/$435.96
Naftin 1% Gel (MERZ PHARMACEUTICAL): 90/$269.99 or 270/$769.94
Naftin 1% Gel (MERZ PHARMACEUTICAL): 60/$216 or 180/$589.99
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions January 2008. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
1. Allergan. Naftin (naftifine hydrochloride) 1% cream prescribing information (dated 1996). In: Physicians’ desk reference. 53rd ed. Montvale, NJ: Medical Economics Company Inc; 1999:501-2.
2. Meingassner JG, Sleytr U, Petranyi G. Morphological changes induced by naftifine, a new antifungal agent, in Trichophyton mentagrophytes. J Invest Dermatol. 1981; 77:444-51. [IDIS 141591] [PubMed 7310168]
3. Ryder NS, Seidl G, Troke PF. Effect of the antimycotic drug naftifine on growth of and sterol biosynthesis in Candida albicans. Antimicrob Agents Chemother. 1984; 25:483-7. [IDIS 184282] [PubMed 6375557]
4. Georgopoulos A, Petranyi G, Mieth H et al. In vitro activity of naftifine, a new antifungal agent. Antimicrob Agents Chemother. 1981; 19:386-9. [IDIS 134653] [PubMed 7247366]
5. Kerridge D. Mode of action of clinically important antifungal drugs. Adv Microbiol Physiol. 1986; 27:1-64.
6. Dittmar W, Jovic N. Laboratory techniques alternative to in vivo experiments for studying the liberation, penetration and fungicidal action of topical antimycotic agents in the skin, including ciclopiroxolamine. Mykosen. 1987; 30:326-42. [PubMed 3657856]
7. Gehse M, Kuster S, Gloor M. On the effective dimension of inhibition of ciclopiroxolamine and naftifine in the horny layer with regard to the galenic preparation. Mykosen. 1987; 30:322-5. [PubMed 3657855]
8. Regli P, Ferrari H, Buffard Y et al. In vitro activity of naftifine, a new antifungal agent, against dermatophytes. Path Biol. 1985; 33:614-7.
9. Petranyi G, Georgopoulos A, Mieth H. In vivo antimycotic activity of naftifine. Antimicrob Agents Chemother. 1981; 19:390-2. [PubMed 7247367]
10. Georgopapadakou NH, Dix BA, Smith SA et al. Effect of antifungal agents on lipid biosynthesis and membrane integrity in Candida albicans. Antimicrob Agents Chemother. 1987; 31:46-51. [PubMed 3551826]
11. Ryder NS. Specific inhibition of fungal sterol biosynthesis by SF 86-327, a new allylamine antimycotic agent. Antimicrob Agents Chemother. 1985; 27:252-6. [PubMed 4039119]
12. Shadomy S, Espinel-Ingroff A, Gebhart RJ. In- vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouraudia. 1985; 23:125-32. [PubMed 2990057]
13. Petranyi G, Ryder NS, Stutz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science. 1984; 224:1239-41. [PubMed 6547247]
14. Ryder NS. Effect of allylamine antimycotic agents on fungal sterol biosynthesis measured by sterol side-chain methylation. J Gen Microbiol. 1985; 131:1595-1602. [PubMed 3900280]
15. Bojanovsky VA, Haas P. Antimycotic effect of naftifine in tinea pedis: comparative double-blind study with bifonazole. Fortschr Med. 1985; 103:677-9. [PubMed 3897005]
16. Ryder NS, Dupong MC. Inhibition of squalene epoxidase by allylamine antimycotic compounds. Biochem J. 1985; 230:765-70. [PubMed 3877503]
17. Grimus RC, Schuster I. The role of the lymphatic transport in the enteral absorption of naftifine by the rat. Xenobiotica. 1984; 14:287-94. [PubMed 6464498]
18. Schatz F, Haberl H, Battig F et al. Major routes of naftifine biotransformation in laboratory animals and man. Arzneimittelforschung. 1986; 36:248-55. [PubMed 3964331]
19. Schatz F, Haberl H. Analytical methods for the determination of naftifine and its metabolites in human plasma and urine. Arzneimittelforschung. 1986; 36:1850-3. [PubMed 3566849]
20. Hoting VE, Kuchmeister B, Hausen BM. Allergic contact dermatitis from naftifine. Dermatosen. 1987; 35:124-7.
21. Hay RJ. Recent advances in the management of fungal infections. Quart J Med. 1987; 244:631-9.
22. Millikan LE, Galen WK, Gewirtzman GB et al. Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis. J Am Acad Dermatol. 1988; 18:52-6. [PubMed 3279083]
23. Ganzinger U, Stutz A, Petranyi G et al. Allylamines: topical and oral treatment of dermatomycoses with a new class of antifungal agents. Acta Derm Venerol (Stockh). 1986; 121:155-60.
24. Hira SK, Abraham MS, Mwinga A et al. Naftifine solution (1%) in the treatment of pityriasis versicolor in Zambia. Mykosen. 1986; 29:378-81. [PubMed 3531847]
25. Zaun H, Liszpinski P. Multicentric double-blind contralateral comparision of naftifine- and clotrimazole-cream in patients with dermatophytosis or Candidosis. Z Hautkr. 1984; 59:1209-17. [PubMed 6388169]
26. Bechter R, Schmid B, Mayer FK. Teratogenic potential of antimycotic drugs evaluated in the whole- embryo culture system. Food Chem Toxicol. 1986; 24:641-2.
27. Berman JD, Gallalee JV. In vitro antileishmanial activity of inhibitors of steroid biosynthesis and combinations of antileishmanial agents. J Parasitol. 1987; 73:671-3. [PubMed 3037057]
28. Klaschka F, Gartmann H, Weidinger G. Antimycotic naftifine: placebo-controlled comparison in tinea pedum. Z Hautkr. 1984; 59:1218-25. [PubMed 6388170]
29. Bechter R, Schmid BP. Teratogenicity in vitro: a comparative study of four antimycotic drugs using the whole-embryo culture system. Toxicol in Vitro. 1987; 1:11-5. [PubMed 20702373]
30. Schuster I. The interaction of representative members from two classes of antimycotics—the azoles and the allylamines—with cytochromes P-450 in steroidogenic tissues and liver. Xenobiotica. 1985; 15:529-46. [PubMed 4036174]
31. Meingassner JG, Sleytr UB. The effects of naftifine on the ultrastructure of Candida parapsilosis: a freeze fracture study. Sabouraudia. 1982; 20:199-207. [PubMed 7135143]
32. Hantschke D, Reichenberger M. Double blind, randomized in vivo investigations comparing the antifungals clotrimazole, tolnaftate and naftifine. Mykosen. 1980; 23:657-68. [PubMed 7012610]
33. Meinicke K, Striegel C, Weidinger G. Treatment of dermatomycoses with naftifine: therapeutic efficacy after once-a-day and twice-a-day application. Mykosen. 1984; 27:608-14. [PubMed 6395017]
34. Nolting S, Weidinger G. Naftifine in severe dermatomycosis: econazole-controlled therapeutic comparison. Mykosen. 1983; 28:69-76.
35. Stutz A, Georgopoulos A, Granitzer W et al. Synthesis and structure-activity relationships of naftifine-related allylamine antimycotics. J Med Chem. 1986; 29:112-25. [PubMed 3510297]
36. Schaude M, Ackerbauer H, Mieth H. Inhibitory effect of antifungal agents on germ tube formation in Candida albicans. Mykosen. 1987; 30:281-7. [PubMed 3306370]
37. Cauwenbergh G. New and prospective developments in antifungal drugs. Acta Derm Venereol (Stockh). 1986; 121:147-53.
38. Faruqi AH, Khan KA, Qazi AA et al. In vitro antifungal activity of naftifine: (SN 105-843 GEL) against dermatophytes. J Pakistan Med Assoc. 1981; 31:279-82.
39. Lee CT, Giam YC, Tan T. The use of naftifine (Exoderil) cream in the treatment of dermatophytosis. Singapore Med J. 1987; 28:429-31. [PubMed 3324355]
40. Stuttgen G. Biopharmaceutical aspects of topically applied antifungal treatment. Mykosen. 1987; 30(Suppl 1):7-14.
41. Ivessa E, Daum G, Paltauf F. Mechanism of action of naftifine. Mykosen. 1987; 30(Suppl 1):15-21.
42. Petranyi G. Preclinical evaluation of Exoderil (naftifine). Part I. Results of experimental studies of the antifungal activity profile. Mykosen. 1987; 30(Suppl 1):22-7.
43. Czok R. Preclinical evaluation of Exoderil (naftifine). Part II. Mechanism of action, absorption, metabolism and excretion. Mykosen. 1987; 30(Suppl 1):28-31. [PubMed 3550458]
44. Obenaus H, Schon H. Preclinical evaluation of Exoderil (naftifine). Part III. Summary of results of toxicological studies. Mykosen. 1987; 30(Suppl 1):32-7.
45. Gip L, Brundin G. A double-blind, two group multicentre study, comparing naftifine 1% cream with placebo cream in the treatment of tinea cruris. Mykosen. 1987; 30:(Suppl 1)38-41.
46. Zaun H, Luszpinski P. Antifungal treatment of hospital inpatients: left versus right study to compare naftifine and clotrimazole. Mykosen. 1987; 30(Suppl 1):42-8.
47. Haas PJ, Tronnier H, Weidinger G. Naftifine in tinea pedis: double-blind comparison with clotrimazole. Mykosen. 1987; 30(Suppl 1):50-6.
48. Maibach HI. Naftifine: dermatotoxicology and clinical efficacy. Mykosen. 1987; 30(suppl 1):57-62. [PubMed 3553928]
49. Kagawa S. Comparative clinical trial of naftifine and clotrimazole in tinea pedum, tinea cruris and tinea corporis. Mykosen. 1987; 30(Suppl 1):63-9.
50. Nolting S, Weidinger G. Naftifine in severe dermatomycoses: econazole-controlled therapeutic comparison. Mykosen. 1987; 30(Suppl 1):70-7.
51. Tronnier H. Inflammatory dermatomycoses: comparative study of naftifine and a combination of a corticosteroid and an imidazole derivative. Mykosen. 1987; 30(Suppl 1):78-87.
52. Jung EG. The anti-inflammatory efficacy of naftifine as evaluated from the erythema response to ultraviolet light. Mykosen. 1987; 30(Suppl 1):88-91.
53. Polemann G. Antifungal efficacy of naftifine applied once-daily. Mykosen. 1987; 30(Suppl 1):92-7.
54. Meinicke K, Striegel C, Weidinger G. Treatment of dermatomycoses with naftifine: therapeutic efficacy on application once daily and twice daily. Mykosen. 1987; 30(Suppl 1):98-103.
55. Effendy I, Friederich HC. Double-blind, randomized comparative study of naftifine solution (once daily) and clotrimazole solution (twice daily) in the treatment of dermatomycoses. Mykosen. 1987; 30(Suppl 1):104-11.
56. Paetzold OH, Engst R, Kneist W et al. Yeast infections of the skin: comparative double-blind therapeutic trial with naftifine and clotrimazole. Mykosen. 1987; 30(Suppl 1):112-8.
57. Klaschka F. Treatment of onychomycosis with naftifine gel. Mykosen. 1987; 30(Suppl 1):119-23.
58. Nolting S. Investigation of the antibacterial effect of the antifungal agent naftifine: left versus right clinical comparative study between naftifine and gentamycin in pyoderma. Mykosen. 1987; 30(Suppl 1):124-8.
59. Anon. Topical neomycin. Med Lett Drugs Ther. 1973; 15:101-2. [PubMed 4765413]
60. Houser E (Herbert Laboratories, Irvine, CA): Personal communication; 1988 Dec.
61. Reviewers’ comments (personal observations); 1988 Dec.
62. Zaias N, Astorga E, Cordero CN et al. Naftifine cream in the treatment of cutaneous candidiasis. Cutis. 1988; 42:238-40. [PubMed 3048914]
63. Allergan. Naftin (naftifine hydrochloride) 1% gel prescribing information (dated 1996). In: Physicians’ desk reference. 53rd ed. Montvale, NJ: Medical Economics Company Inc; 1999:502.
64. Greer DL, Jolly HW Jr. Treatment of tinea cruris with topical terbinafine. J Am Acad Dermatol. 1990; 23:800-4. [PubMed 2229527]
65. Shear NH, Villars VV, Marsolais C. Terbinafine: an oral and topical antifungal agent. Clin Dermatol. 1992; 9:487-95.
66. Lyman CA, Walsh TJ. Systemically administered antifungal agents: a review of their clinical pharmacology and therapeutic applications. Drugs. 1992; 44:9-35. [PubMed 1379913]
67. Anon. Topical terbinafine for tinea infections. Med Lett Drugs Ther. 1993; 35:76-8. [PubMed 8341207]
68. Smith EB. Topical antifungal drugs in the treatment of tinea pedis, tinea cruris, and tinea corporis. J Am Acad Dermatol. 1993; 28(5 Part 1):S24-8. [PubMed 8496408]
69. Gupta AK, Einarson TR, Summerbell RC et al. An overview of topical antifungal therapy in dermatomycoses: a North American perspective. Drugs. 1998; 55:645-74. [PubMed 9585862]
70. Piérard GE, Arrese JE, Piérard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs. 1996; 52:209-24. [PubMed 8841739]
71. Lesher JL. Recent developments in antifungal therapy. Dermatol Clin. 1996; 14:163-9. [PubMed 8821170]
72. Hay RJ. Dermatophytosis and other superficial mycoses. In: Mandel GL, Douglas RG Jr, Bennett JE, eds. Principles and practices of infectious disease. 4th ed. New York: Churchill Livingston; 1995: 2375-86.
73. Drake LA, Dincehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. J Am Acad Dermatol. 1996; 34:282-6. [IDIS 363962] [PubMed 8642094]
74. Reviewers’ comments (personal observations) on Sulconazole 84:04.08.
a. Merz Pharmaceuticals. Naftin (naftifine hydrochloride 1%) gel and cream prescribing information. Greensboro, NC; 2007 May.
